oral glp-1 agonist approved New Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity Oral GLP-1-Based Therapeutics in the
Description
Athauda D, Maclagan K, Skene SS, et al
These findings may have clinical relevance as AUD is associated with polymorphisms in GLP-1-related genes
[DOI] [PubMed] [Google Scholar] 45.Daniels D, Mietlicki-Baase EG
Tests in obese mice indicated the triple agonist was more powerful than dual agonists in correcting obesity and diabetes (Finan, Yang, Ottaway)
How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis
doi: 10.2337/db25-0158
